Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):266–273. doi: 10.1097/QAI.0000000000000957

Table 3. Independent contributions of HIV and HCV controlling for significant fibrosis by APRI on cognitive test performance.

Results from multivariable linear regression analyses of primary and secondary outcome measures.

Cognitive Domains n Primary Predictors
HIV-infection
B (SE)
Hepatitis C positive
B (SE)
Primary Outcomes

Verbal Learning 1467 −1.34 (0.53)* −0.02 (0.71)

  HVLT: Trial 1 1467 −1.46 (0.56)** 0.10 (0.75)
  HVLT: Total Trials 1–3 1467 −1.23 (0.56)* −0.13 (0.75)

Attention and Concentration 1290 −0.83 (0.44) −0.50 (0.59)

  Stroop Trial 1&2 1456 −1.53 (0.64)* −2.58 (0.86)**
  Trail Making Test Part A 1465 −0.28 (0.58) 0.73 (0.78)
  LNS Attention 1305 −1.37 (0.63)* −1.03 (0.84)

Executive Functions 1223 −0.06 (0.51) −0.66 (0.50)

  Stroop Trial 3 1407 −0.32 (0.75) −0.48 (0.73)
  Trail Making Test Part B 1427 −0.07 (0.60) −1.76 (0.81)*
  LNS Working Memory 1270 0.03 (0.67) 0.43 (0.89)

Secondary Outcomes

Verbal Memory 1467 −1.45 (0.53)** 0.94 (0.71)

  HVLT: Delayed free recall 1467 −1.57 (0.56)** 0.78 (0.79)
  HVLT: Percent Retention 1467 −1.33 (0.58)* 1.13 (0.77)

Psychomotor Speed 1459 −0.26 (0.56) −0.28 (0.75)

Fluency 1458 0.19 (0.49) 0.46 (0.66)

  Letter 1460 0.36 (0.59) 0.35 (0.79)
  Semantic 1458 0.07 (0.57) 0.60 (0.76)

Fine Motor Skills 1416 0.18 (0.59) −0.30 (0.79)

  Dominant hand 1444 0.37 (0.60) −0.60 (0.80)
  Non-dominant hand 1416 −0.11 (0.63) −0.12 (0.84)

Note.

***

p<0.001;

**

p<0.01;

*

p<0.05.

HVLT = Hopkins Verbal Learning Test; LNS = Letter-Number Sequence; B = parameter estimates; SE= Standard Errors. All models are adjusted for APRI, site, marijuana use, crack, cocaine, and/or heroin use, smoking, heavy alcohol use, antidepressants, depressive symptoms, body mass index, hypertension, diabetes, income, and number of previous cognitive test exposure.